Baxter International's New Plant to Bring 1,500 High-Paying Jobs
Baxter International Inc. recently announced it will build a new state-of-the-art manufacturing facility in
Baxter expects capital investments at the
”This investment demonstrates our long-term commitment to patients around the world who rely on our plasma-based therapies,” said Robert L. Parkinson, Jr., Baxter’s Chairman and CEO.
Construction will begin this year at the new
”We would like to thank Governor Nathan Deal and the many other officials involved in the site selection process, and we look forward to becoming part of the
In connection with this investment, the company also expects to create more than 200 new positions in
Baxter is a scientific leader and innovator in plasma-derived therapies, with a focus on providing solutions to unmet patient needs. Its products include GAMMAGARD LIQUID (marketed as KIOVIG outside the US and Canada), an immunoglobulin therapy (IG) for people living with primary immunodeficiency (PI), albumin therapies used to treat burns and maintain adequate fluid volume in critically ill patients, as well as blood protein therapies for people suffering from alpha-1 antitrypsin deficiency. The company continues to investigate its treatments in additional areas of significant patient need, including multifocal motor neuropathy and Alzheimer’s disease. These products are produced from plasma that is collected from human donors.
Total Page Views: 1022
